Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details 1)	3 Months Ended		1 Months Ended		3 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2013 USD ($)	Feb. 29, 2012 Samsung Biosimilar Agreement [Member] USD ($)	Feb. 29, 2012 Samsung Biosimilar Agreement [Member] KRW	Mar. 31, 2014 Samsung Biosimilar Agreement [Member] USD ($)	Dec. 31, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Mar. 31, 2013 Samsung Biosimilar Agreement [Member] USD ($)	Mar. 31, 2014 Samsung Biosimilar Agreement [Member] KRW	Dec. 31, 2013 Samsung Biosimilar Agreement [Member] KRW
Schedule of Equity Method Investments [Line Items]
Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals			$ 250,000,000	280,500,000,000
Variable interest entity, qualitative or quantitative information, ownership percentage			85.00%	85.00%
Contribution from Biogen Idec to develop, manufacture and market biosimilar pharmaceuticals			45,000,000	49,500,000,000	17,500,000	23,900,000		18,400,000,000	25,200,000,000
Percentage of stake in entity minimum			15.00%	15.00%	12.00%
Percentage of stake in entity maximum			49.90%	49.90%
Recognized loss	(7,605,000)	(3,811,000)			(7,600,000)		(3,800,000)
Revenue related to technical development and technology transfer services	90,101,000	54,711,000			24,100,000		6,800,000
Research and development expense						36,000,000
Additional milestone payment						$ 85,000,000
Equity Method Investments, Expected Profit Share						50.00%